All News
|
Research Features
More than 30,000 people in the United States live with cystic fibrosis , a life-threatening genetic disorder that causes serious damage to the lungs and digestive system. Though it affects people of all racial and ethnic groups, the disease is most common among Caucasians. And while the median age of people who have it is 42, advances in the treatm...
|
Research Features
More than 30,000 people in the United States live with cystic fibrosis , a life-threatening genetic disorder that causes serious damage to the lungs and digestive system. Though it affects people of all racial and ethnic groups, the disease is most common among Caucasians. And while the median age of people who have it is 42, advances in the treatm...
|
NHLBI in the Press
An antibody used to treat psoriasis and other chronic autoimmune diseases appears to have no effect on aortic inflammation—a key marker for future risk of major cardiovascular events—researchers are reporting.
|
NHLBI in the Press
Catheter ablation for the treatment of atrial fibrillation was no better than drug therapy in improving key patients’ outcomes, according to the intention-to-treat analysis, a statistical concept essential to the interpretation of randomized clinical trials.
|
NHLBI in the Press
Dementia is the leading cause of dependence and disability in the elderly population worldwide. But currently there is no effective medication to treat dementia. Identifying lifestyle-related risk factors, including some that are modifiable, may provide important strategies for preventing dementia.
|
Research Features
Collaborative learning: Innovative research tool helps improve outcomes for congenital heart defects
Congenital heart defects have long posed great risks for the 2.5 million Americans who currently live with them. Now this most common of birth defects has become the focus of an innovative research model that could mean a brighter, healthier future for many children born with this often life-threatening condition. The model, which already has been...
|
NHLBI in the Press
Clare M. Waterman, Ph.D., NIH distinguished investigator and director of the NHLBI Laboratory of Cell and Tissue Morphodynamics has been elected to the National Academy of Sciences (NAS), the highest honor for American scholars in recognition of their distinguished and continuing achievements in ori
|
Research Features
Here’s a sobering thought: Nearly half of Americans with severe asthma do not respond to conventional drugs, leaving them with few ways to minimize the often-debilitating symptoms of the chronic disease. But researchers at NHLBI have developed a new treatment that has the potential to dramatically change that: A synthetic peptide that mimics the wo...
|
Media Availability
WHAT: Hypertension—a major risk factor for heart disease, the leading cause of death in the United States—will take centerstage during Hypertension Awareness Month in May and World Hypertension Day on Thursday, May 17. Experts at the National Heart, Lung, and Blood Institute (NHLBI), where hypertension research has long been a top priority, are ava...
|
NHLBI in the Press
Throughout May 2018, National Asthma and Allergy Awareness Month, the NHLBI wishes to recognize Dr. Esteban Burchard and his team on the 20th anniversary of GALA (Genetics of Asthma in Latino Americans), the largest study of asthma in Latino children in the United States.
|
NHLBI in the Press
Researchers say they have developed a synthetic version of a natural protein called lung surfactant that restored breathing capacity to the injured lungs of rats. The artificial substance could lead to better, cheaper treatments for lung injury in humans, they say.